16. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS.

17. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally.

18. (amended) A use according to claim 9, whereby the condition to be treated is inflammatory or neuropathic pain.

Please add the following new claims:

- - 19. A composition according to claim 11, whereby the mGluR antagonist is a specific mGluR5 antagonist. - -

- - 20. A method according to claim 12, whereby the mGluR antagonist is a specific mGluR5 antagonist. - -

- - 21. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantilly penetrate the CNS. - -

- - 22. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS. - -

- - 23. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved bvy using a mGluR antagonist which does not substantially cross the blood-brain barrier. - -

- - 24. A method according to claim 12, whereby predominant interaction at peripheral receptors Is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier. - -

- - 25. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS. - -